Current and historical daily PE Ratio for Catalyst Pharmaceuticals Inc (
) from 2006 to Apr 25 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Catalyst Pharmaceuticals stock (CPRX) PE ratio as of Apr 25 2024 is 24.79.
More Details
Catalyst Pharmaceuticals Inc (CPRX) PE Ratio (TTM) Chart
Catalyst Pharmaceuticals Inc (CPRX) PE Ratio (TTM) Historical Data
View and export this data going back to 2006. Start your Free Trial
Total 1215
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Catalyst Pharmaceuticals PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-04-25 | 24.8 | 2024-02-21 | 22.5 |
| 2024-04-24 | 24.8 | 2024-02-20 | 22.6 |
| 2024-04-23 | 24.1 | 2024-02-16 | 22.9 |
| 2024-04-22 | 24.8 | 2024-02-15 | 22.8 |
| 2024-04-19 | 24.8 | 2024-02-14 | 22.1 |
| 2024-04-18 | 25.1 | 2024-02-13 | 21.6 |
| 2024-04-17 | 26.2 | 2024-02-12 | 22.4 |
| 2024-04-16 | 25.5 | 2024-02-09 | 22.4 |
| 2024-04-15 | 25.2 | 2024-02-08 | 21.9 |
| 2024-04-12 | 24.9 | 2024-02-07 | 21.9 |
| 2024-04-11 | 25.9 | 2024-02-06 | 22.5 |
| 2024-04-10 | 26.0 | 2024-02-05 | 21.9 |
| 2024-04-09 | 25.9 | 2024-02-02 | 22.3 |
| 2024-04-08 | 25.4 | 2024-02-01 | 23.7 |
| 2024-04-05 | 24.9 | 2024-01-31 | 23.6 |
| 2024-04-04 | 24.8 | 2024-01-30 | 24.2 |
| 2024-04-03 | 25.4 | 2024-01-29 | 23.7 |
| 2024-04-02 | 25.0 | 2024-01-26 | 23.4 |
| 2024-04-01 | 25.8 | 2024-01-25 | 23.8 |
| 2024-03-28 | 26.1 | 2024-01-24 | 23.9 |
| 2024-03-27 | 26.7 | 2024-01-23 | 24.5 |
| 2024-03-26 | 25.8 | 2024-01-22 | 24.8 |
| 2024-03-25 | 26.0 | 2024-01-19 | 23.9 |
| 2024-03-22 | 25.8 | 2024-01-18 | 24.1 |
| 2024-03-21 | 27.3 | 2024-01-17 | 23.9 |
| 2024-03-20 | 27.7 | 2024-01-16 | 23.5 |
| 2024-03-19 | 26.9 | 2024-01-12 | 23.8 |
| 2024-03-18 | 26.4 | 2024-01-11 | 24.1 |
| 2024-03-15 | 26.3 | 2024-01-10 | 24.7 |
| 2024-03-14 | 26.5 | 2024-01-09 | 25.1 |
| 2024-03-13 | 27.3 | 2024-01-08 | 24.8 |
| 2024-03-12 | 26.6 | 2024-01-05 | 23.9 |
| 2024-03-11 | 26.4 | 2024-01-04 | 28.1 |
| 2024-03-08 | 26.6 | 2024-01-03 | 27.3 |
| 2024-03-07 | 27.3 | 2024-01-02 | 28.1 |
| 2024-03-06 | 26.0 | 2023-12-29 | 27.6 |
| 2024-03-05 | 26.7 | 2023-12-28 | 28.2 |
| 2024-03-04 | 27.4 | 2023-12-27 | 33.3 |
| 2024-03-01 | 27.9 | 2023-12-26 | 33.0 |
| 2024-02-29 | 26.3 | 2023-12-22 | 31.9 |
| 2024-02-28 | 23.9 | 2023-12-21 | 30.9 |
| 2024-02-27 | 23.5 | 2023-12-20 | 27.5 |
| 2024-02-26 | 23.3 | 2023-12-19 | 28.3 |
| 2024-02-23 | 23.0 | 2023-12-18 | 27.1 |
| 2024-02-22 | 22.8 | 2023-12-15 | 27.6 |
Catalyst Pharmaceuticals Inc (CPRX) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Catalyst Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US14888U1016
Description
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers